信達生物(01801.HK)信迪利單抗注射液新適應症申請獲批
信達生物(01801.HK)公布,PD-1抑制劑「達伯舒」(信迪利單抗注射液)的新適應症申請,獲得國家藥品監督管理局批准,可聯合培美曲塞和鉑類化療用於非鱗狀非小細胞肺癌(NSCLC)的一線治療。
公司表示,信迪利單抗注射液新適應症申請獲批,為晚期非鱗狀NSCLC患者一線治療提供一種優於現有化療療法的選擇,將使得更多患者獲益。目前信迪利單抗注射液另有三項新適應症申請已獲藥監局受理審評。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.